Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Clinical trial NCT05313022 · UNKNOWN
Trial details
- NCT number
- NCT05313022
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-18
- Primary completion
- 2022-05-13
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.